๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Compound trial record
Trackers Drugs Trial finder
Compound · clinical trials

Cyclophosphamide

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 198 trials in our China, USA, UK, Ireland and India registers that name Cyclophosphamide as an intervention. Synced 25 Sep 2026
198Trials tracked
110Recruiting now
96Lead sponsors
5Country registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 โ€” Top 14 finalist
Compiled from ClinicalTrials.gov registry records ยท Last verified ยท Editorial standards

Cyclophosphamide is named as a drug or biological intervention in 198 clinical trials in our China, USA, UK, Ireland and India trial registers, 110 of which are recruiting. Lead sponsors include Chinese PLA General Hospital (11), Beijing Biotech (9) and Merck Sharp & Dohme LLC (8). Registered phases: Phase 2, Phase 1/2, Phase 3, Phase 1, Phase EARLY_PHASE1, Phase 2/3, Not applicable and Phase 4. Conditions studied include Breast Cancer; Multiple Myeloma; Systemic Sclerosis.

01

Clinical trials of Cyclophosphamide

198 trials
NCT IDStudyPhaseStatusLead sponsorRegister
NCT06092047 UTAA09 Injection in the Treatment of Relapsed/Refractory Hematolymphatic Malignancies. (ClinicalTrials.gov ↗)
CD19-positive Relapsed or Refractory B-cell Malignancies
 Phase EARLY_PHASE1 Recruiting PersonGen BioTherapeutics (Suzhou) Co., Ltd. China
NCT06696833 Allogeneic CD19-targeted CAR-ฮณฮดT Cell Infusion Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia (ClinicalTrials.gov ↗)
B-Cell Acute Lymphoblastic Leukemia, Adult
 Phase EARLY_PHASE1 Recruiting The First Affiliated Hospital of Soochow University China
NCT06756321 A Study of CAR T-Cells in Relapsed/Refractory Hematologic Malignancy (ClinicalTrials.gov ↗)
Relapsed/refractory Lymphoma, Relapsed/Refractory Leukemia
 Phase EARLY_PHASE1 Recruiting Affiliated Hospital of Nantong University China
NCT07144462 A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of NEUK203-215 Injection in Adult Chinese Patients With Relapsed/Refractory Autoimmune Diseases (ClinicalTrials.gov ↗)
Autoimmune
 Phase EARLY_PHASE1 Recruiting Neukio Biotherapeutics (Shanghai) Co., Ltd. China
NCT07077486 Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease (ClinicalTrials.gov ↗)
Lupus or SLE, Interstitial Lung Disease, Systemic Lupus Erythematosus
 Phase 4 Recruiting Tongji Hospital China
NCT01704716 High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)
Neuroblastoma
 Phase 3 Recruiting St. Anna Kinderkrebsforschung Ireland
NCT04043494 International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma
Lymphoblastic Lymphoma, Childhood
 Phase 3 Recruiting University Hospital Muenster Ireland, China
NCT04638790 First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1) (ClinicalTrials.gov ↗)
Hodgkin Lymphoma, Adult
 Phase 3 Recruiting State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia India
NCT05510323 Efficacy of Immunosuppressive Therapy for IgA Nephropathy With Stage 3 or 4 CKD (ClinicalTrials.gov ↗)
Glomerulonephritis, IGA
 Phase 3 Recruiting Air Force Military Medical University, China China
NCT06072612 Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer. (ClinicalTrials.gov ↗)
Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm
 Phase 3 Recruiting BriaCell Therapeutics Corporation USA
NCT06091254 A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma (ClinicalTrials.gov ↗)
Follicular Lymphoma (FL)
 Phase 3 Recruiting Regeneron Pharmaceuticals UK, USA
NCT06091865 A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma (ClinicalTrials.gov ↗)
Diffuse Large B-cell Lymphoma (DLBCL)
 Phase 3 Recruiting Regeneron Pharmaceuticals Ireland, UK, USA
NCT06520176 Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients (ClinicalTrials.gov ↗)
Multiple Myeloma, Hematopoietic Stem Cell Mobilization
 Phase 3 Recruiting The Affiliated People's Hospital of Ningbo University China
NCT06615050 A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203) (ClinicalTrials.gov ↗)
Graft-versus-host Disease (GVHD)
 Phase 3 Recruiting Incyte Corporation USA
NCT06615479 A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2) (ClinicalTrials.gov ↗)
Relapsed or Refractory Multiple Myeloma (RRMM)
 Phase 3 Recruiting Juno Therapeutics, Inc., a Bristol-Myers Squibb Company UK, USA, China
NCT06717347 A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010) (ClinicalTrials.gov ↗)
Diffuse Large B-Cell Lymphoma
 Phase 3 Recruiting Merck Sharp & Dohme LLC USA, China
NCT06911502 A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4) (ClinicalTrials.gov ↗)
Follicular Lymphoma
 Phase 3 Recruiting Celgene UK, USA, India, China
NCT06966700 A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (ClinicalTrials.gov ↗)
Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
 Phase 3 Recruiting Merck Sharp & Dohme LLC UK, USA, India, China
NCT07168161 BDB-001 Phase III Trial in ANCA-Associated Vasculitis (ClinicalTrials.gov ↗)
ANCA Associated Vasculitis (AAV)
 Phase 3 Recruiting Staidson (Beijing) Biopharmaceuticals Co., Ltd China
NCT07362914 Corticosteroids for Doxorubicin Liposome-Induced Hand-Foot-Skin Reactions (ClinicalTrials.gov ↗)
Breast Cancer
 Phase 3 Recruiting Fudan University China
NCT07441460 A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer (ClinicalTrials.gov ↗)
Resectable HER2-positive Breast Cancer
 Phase 3 Recruiting Shanghai JMT-Bio Inc. China
NCT07479797 Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy (ClinicalTrials.gov ↗)
Relapsed or Refractory Large B-cell Lymphoma
 Phase 3 Recruiting Kite, A Gilead Company UK, USA
NCT07764978 Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT (ClinicalTrials.gov ↗)
Newly Diagnosed Multiple Myeloma
 Phase 3 Recruiting AstraZeneca UK, USA
NCT06563245 Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment (ClinicalTrials.gov ↗)
Classical Hodgkin Lymphoma, Child, Adolescent
 Phase 2/3 Recruiting Children's Cancer Group, China China
NCT07634471 A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
Follicular Lymphoma
 Phase 2/3 Recruiting Merck Sharp & Dohme LLC USA, China
NCT04440267 Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage (ClinicalTrials.gov ↗)
Acute Leukemia of Ambiguous Lineage
 Phase 2 Recruiting Institute of Hematology & Blood Diseases Hospital, China China
NCT04792489 DALY II USA/ MB-CART2019.1 for DLBCL (ClinicalTrials.gov ↗)
Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B Cell Lymphoma, High Grade B-cell Lymphoma (HGBCL)
 Phase 2 Recruiting Miltenyi Biomedicine GmbH USA
NCT04920617 DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma
 Phase 2 Recruiting ImmunoVaccine Technologies, Inc. (IMV Inc.) USA
NCT05294055 Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma (ClinicalTrials.gov ↗)
Multiple Myeloma, Lymphoma
 Phase 2 Recruiting Institute of Hematology & Blood Diseases Hospital, China China
NCT05447702 Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (ClinicalTrials.gov ↗)
Triple Negative Breast Cancer
 Phase 2 Recruiting West China Hospital China
NCT05660473 Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ClinicalTrials.gov ↗)
Precursor Cell Lymphoblastic Leukemia-Lymphoma
 Phase 2 Recruiting Institute of Hematology & Blood Diseases Hospital, China China
NCT05845723 Tocilizumab and Tofacitinib in the Treatment of Vascular Behรงet's Syndrome (ClinicalTrials.gov ↗)
Aneurysm, Behcet Syndrome, Vascular Type
 Phase 2 Recruiting Peking Union Medical College Hospital China
NCT05999994 A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer (ClinicalTrials.gov ↗)
Neoplasms, Child, Adolescent
 Phase 2 Recruiting Eli Lilly and Company UK, USA
NCT06140966 Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma (ClinicalTrials.gov ↗)
Multiple Myeloma, Primary Plasma Cell Leukemia, Extramedullary Multiple Myeloma
 Phase 2 Recruiting Union Hospital, Tongji Medical College, Huazhong University of Science and Technology China
NCT06255210 Efficacy and Safety of Induction Chemotherapy for Olfactory Neuroblastoma (ESICON) (ClinicalTrials.gov ↗)
Olfactory Neuroblastoma
 Phase 2 Recruiting Hongmeng Yu China
NCT06389006 To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer (ClinicalTrials.gov ↗)
Breast Cancer
 Phase 2 Recruiting RemeGen Co., Ltd. China
NCT06500273 Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL (ClinicalTrials.gov ↗)
Large B-cell Lymphoma
 Phase 2 Recruiting Allogene Therapeutics USA
NCT06557161 A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of MSD-HSCT Using a TBI or TMLI Conditioning Regimen for Adult ALL (ClinicalTrials.gov ↗)
Acute Lymphoblastic Leukemia, Adult
 Phase 2 Recruiting The First Affiliated Hospital of Zhengzhou University China
NCT06564493 A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of MSD-HSCT Using a TBI or TMLI Conditioning Regimen for Pediatric ALL (ClinicalTrials.gov ↗)
Acute Lymphoblastic Leukemia, Pediatric
 Phase 2 Recruiting The First Affiliated Hospital of Zhengzhou University China
NCT06564545 A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of Haplo-HSCT Using a TBI or TMLI Conditioning Regimen for Adult ALL (ClinicalTrials.gov ↗)
Acute Lymphoblastic Leukemia, Adult
 Phase 2 Recruiting The First Affiliated Hospital of Zhengzhou University China
NCT06700798 Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL๏ผš A Randomized, Open Phase II Trial (ClinicalTrials.gov ↗)
Marginal Zone Lymphoma(MZL)
 Phase 2 Recruiting Fei Li China
NCT06704555 Radiotherapy Followed by Tiselizumab Combined With RCHOP in Previously Untreated Bulky Follicular Lymphoma (ClinicalTrials.gov ↗)
Follicular Lymphoma
 Phase 2 Recruiting Tianjin Medical University Cancer Institute and Hospital China
NCT06797635 Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03) (ClinicalTrials.gov ↗)
Breast Neoplasms, Breast Cancer
 Phase 2 Recruiting Merck Sharp & Dohme LLC USA
NCT06803693 Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL (ClinicalTrials.gov ↗)
Diffuse Large B-Cell Lymphoma
 Phase 2 Recruiting Ruijin Hospital China
NCT06854250 Prostate Cryoablation Combined With Metronomic Cyclophosphamide for Metastatic Prostate Cancer (ClinicalTrials.gov ↗)
Metastatic Prostate Cancer
 Phase 2 Recruiting Sun Yat-sen University China
NCT06890884 A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Lymphoma, Large B-Cell, Diffuse
 Phase 2 Recruiting Merck Sharp & Dohme LLC Ireland, UK, USA
NCT06964906 Neoadjuvant High-Intensity Focused Ultrasound (HIFU) Combined With Toripalimab and Chemotherapy for ER-Positive /HER2-Negative Breast Cancer (ClinicalTrials.gov ↗)
ER+/HER2- Breast Cancer
 Phase 2 Recruiting Second Affiliated Hospital, Zhejiang University, School of Medicine China
NCT07015242 A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma (ClinicalTrials.gov ↗)
Lymphoma
 Phase 2 Recruiting Juno Therapeutics, Inc., a Bristol-Myers Squibb Company USA
NCT07149857 A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel (ClinicalTrials.gov ↗)
Multiple Myeloma
 Phase 2 Recruiting Janssen Research & Development, LLC USA
NCT07224672 A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis
Amyloidosis
 Phase 2 Recruiting GlaxoSmithKline USA
NCT07493148 Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL (ClinicalTrials.gov ↗)
Diffuse Large B-Cell Lymphoma (DLBCL)
 Phase 2 Recruiting Ou Bai, MD/PHD China
NCT07635342 Pyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast Cancer (ClinicalTrials.gov ↗)
HER2-positive Breast Cancer
 Phase 2 Recruiting Hebei Medical University Fourth Hospital China
NCT07719946 To Study Lower Dose of Cyclophosphamide After Stem Cell Transplant for Blood Cancers (ClinicalTrials.gov ↗)
Haploidentical Hematopoietic Stem Cell Transplant, Hematological Malignancies
 Phase 2 Recruiting Tata Memorial Centre India
NCT04146298 Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer (ClinicalTrials.gov ↗)
Pancreatic Cancer, Pancreatic Neoplasms, Pancreatic Ductal Adenocarcinoma
 Phase 1/2 Recruiting Changhai Hospital China
NCT04432714 Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement (ClinicalTrials.gov ↗)
DLBCL, Untreated, MYC Gene Rearrangement
 Phase 1/2 Recruiting The First Affiliated Hospital with Nanjing Medical University China
NCT04625907 FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma (ClinicalTrials.gov ↗)
Rhabdomyosarcoma
 Phase 1/2 Recruiting University of Birmingham Ireland
NCT04989803 Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma (ClinicalTrials.gov ↗)
Relapsed and/or Refractory B-cell Lymphoma
 Phase 1/2 Recruiting Kite, A Gilead Company UK, USA
NCT05323201 Study Of B7H3 CAR-T Cells in Treating Advanced Liver Cancer (ClinicalTrials.gov ↗)
Hepatocellular Carcinoma
 Phase 1/2 Recruiting The Affiliated Hospital of Xuzhou Medical University China
NCT05658640 HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies (ClinicalTrials.gov ↗)
Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent
 Phase 1/2 Recruiting Princess Maxima Center for Pediatric Oncology Ireland
NCT05681650 HER2 Targeted HypoSti.CAR-T Cells in HER2 Positive Advanced Solid Tumors (ClinicalTrials.gov ↗)
HER2 Positive Advanced Solid Tumors
 Phase 1/2 Recruiting Chinese PLA General Hospital China
NCT05693844 Pan-T Booster Co-expressing MSLN CAR T Cell Therapy in Advanced/Metastatic Solid Tumors (ClinicalTrials.gov ↗)
Advanced or Metastatic Solid Tumors
 Phase 1/2 Recruiting Chinese PLA General Hospital China
NCT05699811 IFNฮฑ Expressing Mesenchymal Stromal Cells for Locally Advanced/Metastatic Solid Tumors (ClinicalTrials.gov ↗)
Locally Advanced or Metastatic Solid Tumors
 Phase 1/2 Recruiting Chinese PLA General Hospital China
NCT05745714 HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies (ClinicalTrials.gov ↗)
Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent
 Phase 1/2 Recruiting Princess Maxima Center for Pediatric Oncology Ireland
NCT05751044 HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent
 Phase 1/2 Recruiting Princess Maxima Center for Pediatric Oncology Ireland
NCT05826535 Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma
 Phase 1/2 Recruiting Lyell Immunopharma, Inc. USA
NCT05981014 Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer (ClinicalTrials.gov ↗)
Breast Neoplasms
 Phase 1/2 Recruiting Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University China
NCT06119685 IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
NHL, Multiple Myeloma, Blood Cancer
 Phase 1/2 Recruiting Indapta Therapeutics, INC. USA
NCT06321289 Allogeneic TRAC Locus-inserted CD19-targeting STAR T Cell Therapy in r/r B-NHL (ClinicalTrials.gov ↗)
Non-hodgkin Lymphoma,B Cell
 Phase 1/2 Recruiting Chinese PLA General Hospital China
NCT06481735 TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL (ClinicalTrials.gov ↗)
Acute Lymphocytic Leukemia
 Phase 1/2 Recruiting Chinese PLA General Hospital China
NCT06530303 Biological Tumor Infiltrating Lymphocytes Therapy With Immunotherapy for Colon and Rectum Cancer (ClinicalTrials.gov ↗)
Colorectal Cancer, Colon Cancer, Rectum Cancer
 Phase 1/2 Recruiting Essen Biotech China
NCT06538012 TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer (ClinicalTrials.gov ↗)
Lung Cancer, Lung Cancer Metastatic, Lung Cancer, Non-small Cell
 Phase 1/2 Recruiting Essen Biotech China
NCT06564038 A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma
 Phase 1/2 Recruiting AstraZeneca UK, USA, China
NCT06640582 TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas (ClinicalTrials.gov ↗)
Brain Tumor, Brain Metastases, Brain Cancer
 Phase 1/2 Recruiting Essen Biotech China
NCT06680752 Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS (ClinicalTrials.gov ↗)
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory, MDS (Myelodysplastic Syndrome)
 Phase 1/2 Recruiting ARCE Therapeutics, Inc. USA
NCT06720324 CD7-specific CAR-T Cell in the Treatment of CD7-positive Relapsed/Refractory Hematologic Tumors (ClinicalTrials.gov ↗)
Hematologic Malignancy
 Phase 1/2 Recruiting Union Hospital, Tongji Medical College, Huazhong University of Science and Technology China
NCT06721962 Treatment of Moderate to Severe Refractory Crohn's Disease (ClinicalTrials.gov ↗)
Crohns Disease
 Phase 1/2 Recruiting Tr1X, Inc. USA
NCT06733935 A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2) (ClinicalTrials.gov ↗)
Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
 Phase 1/2 Recruiting Nkarta, Inc. USA
NCT06838832 Novel Allogenic CD19-targeting CAR-ฮณฮดT Cell Therapy (QH103E) in r/r NHL (ClinicalTrials.gov ↗)
Non-hodgkin Lymphoma,B Cell
 Phase 1/2 Recruiting Chinese PLA General Hospital China
NCT06897930 A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE (ClinicalTrials.gov ↗)
Lupus Erythematosus, Systemic
 Phase 1/2 Recruiting AstraZeneca UK, USA
NCT07009002 BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma (ClinicalTrials.gov ↗)
B Cell Lymphoma
 Phase 1/2 Recruiting Chinese PLA General Hospital China
NCT07124936 A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma (ClinicalTrials.gov ↗)
Diffuse Large B Cell Lymphoma (DLBCL)
 Phase 1/2 Recruiting Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. China
NCT07500220 Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC (ClinicalTrials.gov ↗)
Advanced Hepatocellular Carcinoma (HCC), Metastatic Liver Cancer
 Phase 1/2 Recruiting Beijing Biotech China
NCT07502287 Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma
Relapsed Neuroblastoma, Refractory Neuroblastoma, High-Risk Neuroblastoma
 Phase 1/2 Recruiting Beijing Biotech China
NCT07510815 Dual-Target MSLN/FAP CAR-NK Cells for Pleural and Peritoneal Mesothelioma (ClinicalTrials.gov ↗)
Malignant Pleural Mesotheliomas
 Phase 1/2 Recruiting Beijing Biotech China
NCT07570563 Clinical Study of the Safety and Efficacy of Allogeneic TCR-enhanced Vฮด2 T Cell in Patients With Malignant Tumors. (ClinicalTrials.gov ↗)
Hematologic Malignancy, Solid Tumor
 Phase 1/2 Recruiting Chinese PLA General Hospital China
NCT07589543 Dual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer (ClinicalTrials.gov ↗)
Epithelial Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube or Peritoneum
 Phase 1/2 Recruiting Beijing Biotech China
NCT07598955 Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma (ClinicalTrials.gov ↗)
B2 Thymoma, Thymic Carcinoma
 Phase 1/2 Recruiting Beijing Biotech China
NCT07641036 Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer (ClinicalTrials.gov ↗)
Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma
 Phase 1/2 Recruiting Beijing Biotech China
NCT03666000 Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
Non-Hodgkin Lymphoma, B-cell Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia
 Phase 1 Recruiting Imugene Limited USA
NCT05618925 Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma
Non Hodgkin's Lymphoma Refractory/Relapsed
 Phase 1 Recruiting ImmunityBio, Inc. USA
NCT05631886 Combination of CAR-DC Vaccine and ICIs in Malignant Tumors (ClinicalTrials.gov ↗)
Solid Tumor, Adult, Lymphoma, EphA2 Overexpression
 Phase 1 Recruiting Chinese PLA General Hospital China
NCT05952947 HRYZ-T101 Injection for HPV18 Positive Solid Tumor (ClinicalTrials.gov ↗)
Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Carcinoma of Vagina
 Phase 1 Recruiting HRYZ Biotech Co. China
NCT06121570 Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer (ClinicalTrials.gov ↗)
Breast Neoplasms
 Phase 1 Recruiting Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University China
NCT06241456 FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors (ClinicalTrials.gov ↗)
Advanced Solid Tumor
 Phase 1 Recruiting Fate Therapeutics USA
NCT06302062 Phase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid Tumors (ClinicalTrials.gov ↗)
Advanced Solid Tumor, Tumor Associated Lymph Node T Cell, Immunotherapy
 Phase 1 Recruiting Guangzhou FineImmune Biotechnology Co., LTD. China
NCT06308978 A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease (ClinicalTrials.gov ↗)
Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM), Systemic Sclerosis (SSc)
 Phase 1 Recruiting Fate Therapeutics UK, USA
NCT06415487 ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)
Locally Advanced Solid Tumor, Metastatic Solid Tumor
 Phase 1 Recruiting Acepodia Biotech, Inc. USA
NCT06708845 US Zamto-cel Autoimmune Diseases (ClinicalTrials.gov ↗)
Lupus Nephritis, Systemic Lupus Erythematosus, Systemic Sclerosis (SSc)
 Phase 1 Recruiting Miltenyi Biomedicine GmbH USA
NCT06809699 Human Leukocyte Antigen (HLA) Mismatched Related Allogeneic Hematopoietic Stem Cell Transplantation (ClinicalTrials.gov ↗)
Hematologic Diseases
 Phase 1 Recruiting He Huang China
NCT06834282 CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF) (ClinicalTrials.gov ↗)
AML, Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
 Phase 1 Recruiting CERo Therapeutics Holdings, Inc. USA
NCT06898385 A Phase I Clinical Study of IX001 TCR-T Injection in the Treatment of Advanced Pancreatic Cancer Patients With KRAS G12V Mutation (ClinicalTrials.gov ↗)
Pancreatic Cancer
 Phase 1 Recruiting Sun Yat-sen University China
NCT07085104 A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease (ClinicalTrials.gov ↗)
Systemic Lupus Erythematosus (With and Without Nephritis), Idiopathic Inflammatory Myopathy, Systemic Sclerosis
 Phase 1 Recruiting Allogene Therapeutics USA
NCT07178171 A Study of QL1706 Combined With Short-Cycle Anthracyclines or Taxanes for the Treatment of Early-Stage TNBC (ClinicalTrials.gov ↗)
TNBC, Triple Negative Breast Cancer
 Phase 1 Recruiting Xijing Hospital China
NCT07304154 A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases (ClinicalTrials.gov ↗)
Chronic Inflammatory Demyelinating Polyneuropathy, Myasthenia Gravis, Multiple Sclerosis
 Phase 1 Recruiting Kite, A Gilead Company USA
NCT07480941 Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma (ClinicalTrials.gov ↗)
Glioblastoma, High-grade Glioma, Malignant Glioma
 Phase 1 Recruiting Beijing Biotech China
NCT07492628 Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma (ClinicalTrials.gov ↗)
Bladder Cancer, Urothelial Carcinoma, Metastatic Urothelial Carcinoma
 Phase 1 Recruiting Beijing Biotech China
NCT07526493 Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases. (ClinicalTrials.gov ↗)
Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorder (NMOSD), Autoimmune Encephalitis (AE)
 Phase 1 Recruiting Tongji Hospital China
NCT07613723 A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid Malignancies (ClinicalTrials.gov ↗)
Ovarian Cancer, Squamous Non-Small Cell Lung Cancer (NSCLC), Synovial Sarcomas
 Phase 1 Recruiting Zelluna Immunotherapy AS UK
NCT07641049 Dual-target PSMA/PSCA CAR-NK Cells in Advanced Prostate Cancer (ClinicalTrials.gov ↗)
Metastatic Castration-resistant Prostate Cancer, Advanced Prostate Adenocarcinoma, PSCA-positive Prostate Cancer
 Phase 1 Recruiting Beijing Biotech China
NCT07010523 Anti-Mesothelin CAR-T Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid Tumors (ClinicalTrials.gov ↗)
Mesothelin-positive Advanced Malignant Solid Tumors
 Not applicable Recruiting First Affiliated Hospital of Zhejiang University China
NCT07342738 TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors (ClinicalTrials.gov ↗)
KRAS G12V, KRAS G12D, Solid Tumor
 Phase EARLY_PHASE1 Not yet open Sun Yat-sen University China
NCT07335562 A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis (ClinicalTrials.gov ↗)
Systemic Sclerosis
 Phase 3 Not yet open Juno Therapeutics, Inc., a Bristol-Myers Squibb Company UK, USA
NCT07719855 A Multicenter, Prospective, Open-Label, Randomized Controlled Clinical Study of Orelabrutinib Combined With Obinutuzumab and Lenalidomide Versus Obinutuzumab Plus Chemotherapy for Treatment-Naive Follicular Lymphoma (ClinicalTrials.gov ↗)
Follicular Lymphoma ( FL)
 Phase 3 Not yet open Ruijin Hospital China
NCT07735637 A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6). (ClinicalTrials.gov ↗)
Newly Diagnosed Multiple Myeloma (NDMM)
 Phase 3 Not yet open AstraZeneca UK, USA
NCT05303727 Allogeneic Hematopoietic Stem Cell Transplantation for 4/M Neuroblastoma (ClinicalTrials.gov ↗)
Neuroblastoma
 Phase 2 Not yet open Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University China
NCT06614985 The Efficacy and Safety of Treatment With Telitacicept in Primary Membranous Nephropathy (ClinicalTrials.gov ↗)
Primary Membranous Nephropathy
 Phase 2 Not yet open Renmin Hospital of Wuhan University China
NCT06713057 Efficacy of Organoid-Based Chemotherapy Drug Precision Screening to Guide Treatment for Thyroid Cancer (ClinicalTrials.gov ↗)
Locally Advanced Thyroid Gland Carcinoma, Thyroid Cancer
 Phase 2 Not yet open West China Hospital China
NCT07034508 A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1 (ClinicalTrials.gov ↗)
DLBCL - Diffuse Large B Cell Lymphoma
 Phase 2 Not yet open Institute of Hematology & Blood Diseases Hospital, China China
NCT07137884 Anlotinib Hydrochloride Capsules in Maintenance Treatment for Intermediate-High Risk Rhabdomyosarcoma in Children (ClinicalTrials.gov ↗)
Rhabdomyosarcoma Recurrent, Maintenance Treatment
 Phase 2 Not yet open Sun Yat-sen University China
NCT07231250 Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma (ClinicalTrials.gov ↗)
DLBCL - Diffuse Large B Cell Lymphoma, Chemo-free Therapy, Bispecific Antibody
 Phase 2 Not yet open Li Zhiming China
NCT07301138 BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia Patients (ClinicalTrials.gov ↗)
Acute Lymphoblastic Leukemia
 Phase 2 Not yet open Ruijin Hospital China
NCT07535762 Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Untreated Peripheral T-Cell Lymphoma (ClinicalTrials.gov ↗)
Peripheral T-Cell Lymphoma (PTCL NOS), Nodal T-follicular Helper Cell Lymphoma, Anaplastic Large Cell Lymphoma (ALCL) (ALK-1 Negative)
 Phase 2 Not yet open Shanghai Jiao Tong University School of Medicine China
NCT07594899 AI-Driven Treatment Strategy vs Pola-R-CHP in Untreated LBCL (ClinicalTrials.gov ↗)
Large B-Cell Lymphoma (LBCL)
 Phase 2 Not yet open Ruijin Hospital China
NCT07603557 Study of Zola-cel (BMS-986353), in Participants With Autoimmune Cytopenia (Breakfree-AiCE) (ClinicalTrials.gov ↗)
Chronic Immune Thrombocytopenia, Autoimmune Hemolytic Anemia
 Phase 2 Not yet open Juno Therapeutics, Inc., a Bristol-Myers Squibb Company UK, USA
NCT07613788 Rimegepant Plus Glofitamab and CD19 CAR-T Therapy in R/R LBCL (ClinicalTrials.gov ↗)
Relapsed/Refractory Large B-cell Lymphoma (LBCL)
 Phase 2 Not yet open Ruijin Hospital China
NCT07676175 A Study of BEBT-908 in Combination With Chemotherapy in Patients With Previously Untreated Peripheral T-Cell Lymphoma (PTCL) (ClinicalTrials.gov ↗)
Previously Untreated Peripheral T-Cell Lymphoma
 Phase 2 Not yet open BeBetter Med Inc China
NCT07746245 The Efficacy of CAPCT in Patients With PTCL (ClinicalTrials.gov ↗)
Peripheral T-Cell Lymphoma
 Phase 2 Not yet open The First Affiliated Hospital with Nanjing Medical University China
NCT06939270 CD73/AXL Targeted HypoSti.CAR-T Cells in CD73/AXL Positive Advanced/Metastatic Solid Tumors (ClinicalTrials.gov ↗)
Solid Tumor
 Phase 1/2 Not yet open Chinese PLA General Hospital China
NCT07535710 Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-cell Lymphoma (ClinicalTrials.gov ↗)
Cutaneous T-Cell Lymphoma Refractory, Cutaneous T-Cell Lymphoma, Relapsed, Sezary Syndrome
 Phase 1/2 Not yet open Shanghai Jiao Tong University School of Medicine China
NCT07638787 Pola-R-CHP Plus Sonrotoclax in Untreated BCL2-High/Double-Hit LBCL (ClinicalTrials.gov ↗)
Large B-cell Lymphoma
 Phase 1/2 Not yet open Ruijin Hospital China
NCT07793435 A Phase 1/2 Trial of ADI-212 in mCRPC (ClinicalTrials.gov ↗)
Prostate Cancer Metastatic
 Phase 1/2 Not yet open Adicet Therapeutics USA
NCT07818499 A Study of BL-M08D1 in Combination With Immunochemotherapy in Patients With Diffuse Large B-Cell Lymphoma (ClinicalTrials.gov ↗)
Diffuse Large B-Cell Lymphoma
 Phase 1/2 Not yet open Sichuan Baili Pharmaceutical Co., Ltd. China
NCT06373991 A Study to Evaluate the Safety and Efficacy of ATHENA CAR-T in Subjects With Systemic Lupus Erythematosus (ClinicalTrials.gov ↗)
Lupus Erythematosus, Systemic
 Phase 1 Not yet open EdiGene Inc. China
NCT07024147 JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma (ClinicalTrials.gov ↗)
B-Cell Non-Hodgkin Lymphoma, Large B Cell Diffuse Lymphoma, Follicular Lymphoma
 Phase 1 Not yet open Peking University Cancer Hospital & Institute China
NCT07105176 HS-IT101 Injection for Advanced NSCLC (ClinicalTrials.gov ↗)
Advanced Non-Small Cell Lung Cancer
 Phase 1 Not yet open Qingdao Sino-Cell Biomedicine Co., Ltd. China
NCT07491263 Clinical Study of Universal CD19 CAR-ฮณฮด T Cell Infusion in the Treatment of Relapsed/Refractory Acute B Lymphoblastic Leukemia (ClinicalTrials.gov ↗)
Relapsed/Refractory CD19-positive B-ALL
 Phase 1 Not yet open Fujian Medical University China
NCT05287308 Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world Study (ClinicalTrials.gov ↗)
Breast Cancer
 Not applicable Not yet open Chinese Academy of Medical Sciences China
NCT06499025 Treatment of Relapsed or Refractory t(8; 21) AML With Targeted AML1-ETO Neoantigen Cytotoxic T Cells (CTL) (ClinicalTrials.gov ↗)
AML, t(8;21), Neoantigen
 Phase EARLY_PHASE1 By invitation BGI, China China
NCT05678933 AC-CHOP Versus CHOP in Patients With Previously Untreated PTCL-TFH (ClinicalTrials.gov ↗)
Peripheral T-cell Lymphoma Targeted Therapy
 Phase 3 By invitation Tianjin Medical University Cancer Institute and Hospital China
NCT06468943 Polatuzumab Vedotin and Zanubrutinib Plus R-CHP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL (ClinicalTrials.gov ↗)
Effects of Chemotherapy, Safety Issues
 Phase 2 By invitation The First Affiliated Hospital of Soochow University China
NCT06375993 A Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease (ClinicalTrials.gov ↗)
Lupus Nephritis, Autoimmune Diseases, Systemic Sclerosis (SSc)
 Phase 1 By invitation Adicet Therapeutics USA
NCT07038447 A Study of KITE-363 in Participants With Refractory Autoimmune Diseases (ClinicalTrials.gov ↗)
Systemic Lupus Erythematosus, Lupus Nephritis, Systemic Sclerosis
 Phase 1 By invitation Kite, A Gilead Company USA
NCT05300932 A Study Evaluating the Efficacy and Safety of Baricitinib in Systemic Sclerosis (ClinicalTrials.gov ↗)
Systemic Sclerosis
 Phase 4 Active, closed Tongji Hospital China
NCT02724163 International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia
Acute Myeloid Leukaemia
 Phase 3 Active, closed University of Birmingham Ireland
NCT03725059 Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)
Breast Cancer
 Phase 3 Active, closed Merck Sharp & Dohme LLC Ireland, UK, USA, China
NCT04193059 Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer (ClinicalTrials.gov ↗)
Breast Cancer
 Phase 3 Active, closed Fudan University China
NCT04529772 A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) (ClinicalTrials.gov ↗)
Diffuse Large B-Cell Lymphoma
 Phase 3 Active, closed Acerta Pharma BV USA, India, China
NCT04547049 A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) From Young Non-first-degree and Older First-degree Donors in Hematological Malignancies (ClinicalTrials.gov ↗)
Leukemia, MDS
 Phase 3 Active, closed First Affiliated Hospital of Zhejiang University China
NCT04824092 Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients (ClinicalTrials.gov ↗)
Diffuse Large B-cell Lymphoma
 Phase 3 Active, closed Incyte Corporation Ireland, UK, USA
NCT04923893 A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy (ClinicalTrials.gov ↗)
Multiple Myeloma
 Phase 3 Active, closed Janssen Research & Development, LLC Ireland, UK, USA
NCT05113251 Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer (ClinicalTrials.gov ↗)
Breast Neoplasms, Breast Cancer, HER2-positive Early Breast Cancer
 Phase 3 Active, closed AstraZeneca USA, India, China
NCT05371093 Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma (ClinicalTrials.gov ↗)
Relapsed/Refractory Follicular Lymphoma
 Phase 3 Active, closed Kite, A Gilead Company UK, USA
NCT05578976 A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
Diffuse Large B-Cell Lymphoma
 Phase 3 Active, closed Genmab UK, USA, China
NCT05605899 Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma
High-risk Large B-cell Lymphoma (LBCL)
 Phase 3 Active, closed Kite, A Gilead Company UK, USA
NCT05624554 A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008) (ClinicalTrials.gov ↗)
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
 Phase 3 Active, closed Merck Sharp & Dohme LLC USA, China
NCT06045806 A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
Multiple Myeloma
 Phase 3 Active, closed Celgene UK, USA
NCT06047080 An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
Large B-Cell Lymphoma
 Phase 3 Active, closed Hoffmann-La Roche UK, USA, China
NCT06097364 A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma (ClinicalTrials.gov ↗)
Follicular Lymphoma (FL)
 Phase 3 Active, closed Regeneron Pharmaceuticals UK, USA
NCT06112379 A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (ClinicalTrials.gov ↗)
Breast Cancer
 Phase 3 Active, closed AstraZeneca UK, USA, India, China
NCT06191744 Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (ClinicalTrials.gov ↗)
Follicular Lymphoma (FL)
 Phase 3 Active, closed Genmab UK, USA, China
NCT06356129 Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma (ClinicalTrials.gov ↗)
Large B-cell Lymphoma
 Phase 3 Active, closed Celgene USA, India, China
NCT06413498 A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma (ClinicalTrials.gov ↗)
Multiple Myeloma
 Phase 3 Active, closed Kite, A Gilead Company UK, USA
NCT02641847 TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature (ClinicalTrials.gov ↗)
Triple Negative Breast Cancer, Breast Cancer
 Phase 2/3 Active, closed Fudan University China
NCT03418779 Treatment Effects of Chinese Medicine (Yi-Qi-Qing-Jie Herbal Compound) Combined With Immunosuppression Therapies in IgA Nephropathy Patients With High-risk of ESRD (ClinicalTrials.gov ↗)
IgA Nephropathy at High Risk of Developing ESRD
 Phase 2/3 Active, closed Guang'anmen Hospital of China Academy of Chinese Medical Sciences China
NCT03407144 Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)
Hodgkin Lymphoma
 Phase 2 Active, closed Merck Sharp & Dohme LLC UK, USA
NCT03709680 Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors (ClinicalTrials.gov ↗)
Ewing Sarcoma, Solid Tumors, Rhabdoid Tumor
 Phase 2 Active, closed Pfizer UK, USA, India
NCT03836352 Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors
Ovarian Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer
 Phase 2 Active, closed ImmunoVaccine Technologies, Inc. (IMV Inc.) USA
NCT03967223 Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors
Neoplasms
 Phase 2 Active, closed USWM CT, LLC UK, USA
NCT04172259 ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC
Breast Cancer, Neoadjuvant Chemotherapy
 Phase 2 Active, closed Sun Yat-sen University China
NCT04245839 A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL) (ClinicalTrials.gov ↗)
Lymphoma, Non-Hodgkin
 Phase 2 Active, closed Celgene UK, USA
NCT04390399 Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer (ClinicalTrials.gov ↗)
Pancreatic Cancer
 Phase 2 Active, closed ImmunityBio, Inc. USA
NCT04931342 A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors (ClinicalTrials.gov ↗)
Ovarian Cancer
 Phase 2 Active, closed Hoffmann-La Roche UK, USA
NCT04980222 A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma
Lymphoma
 Phase 2 Active, closed Hoffmann-La Roche USA
NCT05250973 A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis (ClinicalTrials.gov ↗)
Amyloidosis
 Phase 2 Active, closed Janssen Research & Development, LLC UK, USA, China
NCT05283720 A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Non-Hodgkin Lymphoma
 Phase 2 Active, closed Genmab USA, China
NCT05673785 A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL) (ClinicalTrials.gov ↗)
Lymphoma
 Phase 2 Active, closed Takeda China
NCT06093841 Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL (ClinicalTrials.gov ↗)
Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma Grade 3B, High-grade B-cell Lymphoma
 Phase 2 Active, closed Shanghai Ming Ju Biotechnology Co., Ltd. China
NCT06425302 A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma (ClinicalTrials.gov ↗)
Lymphoma, Follicular
 Phase 2 Active, closed Celgene UK, USA
NCT06577025 A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma (ClinicalTrials.gov ↗)
Multiple Myeloma
 Phase 2 Active, closed Janssen Research & Development, LLC USA
NCT07015983 A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE) (ClinicalTrials.gov ↗)
Lupus Erythematosus, Systemic, Lupus Nephritis
 Phase 2 Active, closed Juno Therapeutics, Inc., a Bristol-Myers Squibb Company UK, USA
NCT03907852 Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer (ClinicalTrials.gov ↗)
Mesothelioma, Mesothelioma, Malignant, Mesothelioma; Pleura
 Phase 1/2 Active, closed TCR2 Therapeutics USA
NCT04416984 Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2) (ClinicalTrials.gov ↗)
Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma
 Phase 1/2 Active, closed Allogene Therapeutics USA
NCT04697940 Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHL (ClinicalTrials.gov ↗)
Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma, Decitabine-primed Tandem CD19/CD20 CAR T Cells
 Phase 1/2 Active, closed Han weidong China
NCT05201248 A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma (ClinicalTrials.gov ↗)
B-Cell Non-Hodgkin Lymphoma
 Phase 1/2 Active, closed Genmab China
NCT06480565 A Phase 1/2 Trial of ADI-270 in ccRCC (ClinicalTrials.gov ↗)
Clear Cell Renal Cell Carcinoma
 Phase 1/2 Active, closed Adicet Therapeutics USA
NCT04106219 A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma (ClinicalTrials.gov ↗)
Neuroblastoma
 Phase 1 Active, closed Eli Lilly and Company UK, USA
NCT04629729 FT819 in Subjects With B-cell Malignancies (ClinicalTrials.gov ↗)
Lymphoma, B-Cell, Chronic Lymphocytic Leukemia, Precursor B-Cell Acute Lymphoblastic Leukemia
 Phase 1 Active, closed Fate Therapeutics USA
NCT04667663 CPD-DARA in Patients With Relapsed/Refractory Multiple Myeloma. (ClinicalTrials.gov ↗)
Multiple Myeloma
 Phase 1 Active, closed Cancer Trials Ireland Ireland
NCT04884035 Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma (ClinicalTrials.gov ↗)
Lymphoma, B-Cell
 Phase 1 Active, closed Celgene USA
NCT05631899 CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors (ClinicalTrials.gov ↗)
Solid Tumor, Adult, EphA2 Overexpression, KRAS G12V
 Phase 1 Active, closed Chinese PLA General Hospital China
NCT05665062 Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies (ClinicalTrials.gov ↗)
CLL/SLL, NHL, Mantle Cell Lymphoma
 Phase 1 Active, closed Synthekine USA
NCT05869955 A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1) (ClinicalTrials.gov ↗)
Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy, Systemic Sclerosis
 Phase 1 Active, closed Juno Therapeutics, Inc., a Bristol-Myers Squibb Company USA
NCT06079164 Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell Lymphoma (ClinicalTrials.gov ↗)
Relapsed/Refractory Large B-cell Lymphoma
 Phase 1 Active, closed Kite, A Gilead Company USA
NCT06220201 A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2) (ClinicalTrials.gov ↗)
Multiple Sclerosis, Myasthenia Gravis
 Phase 1 Active, closed Juno Therapeutics, Inc., a Bristol-Myers Squibb Company UK, USA
NCT06265220 AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus (ClinicalTrials.gov ↗)
Lupus Nephritis - WHO Class III, Lupus Nephritis - WHO Class IV, Refractory Systemic Lupus Erythematosus
 Phase 1 Active, closed Artiva Biotherapeutics, Inc. USA
NCT07008378 A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Pharmacodynamics of P-CD19CD20-ALLO1 in Participants With Multiple Sclerosis (ClinicalTrials.gov ↗)
Multiple Sclerosis
 Phase 1 Active, closed Genentech, Inc. USA
NCT03936829 Cyclophosphamide in the Treatment of Associated Acquired Lipodystrophy Syndrome With Type 1 Diabetes (ClinicalTrials.gov ↗)
Lipodystrophy Acquired, Type1diabetes
 Not applicable Active, closed Children's Hospital of Fudan University China
NCT07155369 UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases (ClinicalTrials.gov ↗)
Systemic Lupus Erythematosus, Systemic Sclerosis
 Not applicable Active, closed The Affiliated Hospital of Xuzhou Medical University China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

02

Conditions studied

259 conditions
Condition (as registered)Trials
Breast Cancer11
Multiple Myeloma10
Systemic Sclerosis7
Diffuse Large B-Cell Lymphoma5
Large B-cell Lymphoma5
Breast Neoplasms5
Follicular Lymphoma5
Lymphoma5
Systemic Lupus Erythematosus5
Lupus Nephritis4
Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent3
Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent3
Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory3
Neuroblastoma3
Small Lymphocytic Lymphoma3
Lupus Erythematosus, Systemic3
Systemic Sclerosis (SSc)3
Follicular Lymphoma (FL)3
Ovarian Cancer3
Multiple Sclerosis3
Non-Hodgkin Lymphoma3
Chronic Lymphocytic Leukemia3
Pancreatic Cancer3
Idiopathic Inflammatory Myopathy3
Solid Tumor3
Lymphoma, Large B-Cell, Diffuse2
Acute Lymphoblastic Leukemia2
Rhabdomyosarcoma2
Acute Lymphoblastic Leukemia, in Relapse2
Neoplasms2
Systemic Lupus Erythematosus (SLE)2
Myasthenia Gravis2
Amyloidosis2
Child2
Adolescent2
NHL2
Refractory Non-Hodgkin Lymphoma2
Hepatocellular Carcinoma2
Bladder Cancer2
AML2

+ 219 more conditions in the trial records above.

03

Sponsors

lead sponsor per trial
Lead sponsorTrials
Chinese PLA General Hospital11
Beijing Biotech9
Merck Sharp & Dohme LLC8
Kite, A Gilead Company8
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company7
AstraZeneca6
Celgene6
Ruijin Hospital6
Sun Yat-sen University5
Janssen Research & Development, LLC4
Genmab4
Institute of Hematology & Blood Diseases Hospital, China4
Princess Maxima Center for Pediatric Oncology3
Regeneron Pharmaceuticals3
Hoffmann-La Roche3
Fate Therapeutics3
Allogene Therapeutics3
Adicet Therapeutics3
The First Affiliated Hospital of Zhengzhou University3
Tongji Hospital3
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University3
Essen Biotech3
Fudan University3
University of Birmingham2
Incyte Corporation2
Eli Lilly and Company2
ImmunoVaccine Technologies, Inc. (IMV Inc.)2
ImmunityBio, Inc.2
Miltenyi Biomedicine GmbH2
Tianjin Medical University Cancer Institute and Hospital2
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology2
West China Hospital2
First Affiliated Hospital of Zhejiang University2
The First Affiliated Hospital of Soochow University2
The First Affiliated Hospital with Nanjing Medical University2
Shanghai Jiao Tong University School of Medicine2
The Affiliated Hospital of Xuzhou Medical University2
University Hospital Muenster1
St. Anna Kinderkrebsforschung1
Cancer Trials Ireland1
USWM CT, LLC1
Zelluna Immunotherapy AS1
Pfizer1
GlaxoSmithKline1
Indapta Therapeutics, INC.1
Lyell Immunopharma, Inc.1
Imugene Limited1
Acepodia Biotech, Inc.1
CERo Therapeutics Holdings, Inc.1
Artiva Biotherapeutics, Inc.1
TCR2 Therapeutics1
Acerta Pharma BV1
Genentech, Inc.1
Synthekine1
BriaCell Therapeutics Corporation1
Nkarta, Inc.1
Tr1X, Inc.1
ARCE Therapeutics, Inc.1
State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia1
Tata Memorial Centre1
Air Force Military Medical University, China1
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.1
Qingdao Sino-Cell Biomedicine Co., Ltd.1
He Huang1
Hebei Medical University Fourth Hospital1
BeBetter Med Inc1
Fujian Medical University1
Staidson (Beijing) Biopharmaceuticals Co., Ltd1
Children's Hospital of Fudan University1
Second Affiliated Hospital, Zhejiang University, School of Medicine1
Li Zhiming1
Han weidong1
Shanghai JMT-Bio Inc.1
Affiliated Hospital of Nantong University1
Peking University Cancer Hospital & Institute1
PersonGen BioTherapeutics (Suzhou) Co., Ltd.1
Children's Cancer Group, China1
Hongmeng Yu1
BGI, China1
Changhai Hospital1
EdiGene Inc.1
Guang'anmen Hospital of China Academy of Chinese Medical Sciences1
Chinese Academy of Medical Sciences1
Guangzhou FineImmune Biotechnology Co., LTD.1
Ou Bai, MD/PHD1
Neukio Biotherapeutics (Shanghai) Co., Ltd.1
HRYZ Biotech Co.1
RemeGen Co., Ltd.1
Sichuan Baili Pharmaceutical Co., Ltd.1
Xijing Hospital1
Shanghai Ming Ju Biotechnology Co., Ltd.1
Peking Union Medical College Hospital1
Fei Li1
Renmin Hospital of Wuhan University1
The Affiliated People's Hospital of Ningbo University1
Takeda1
04

Trials by country register

RegisterCyclophosphamide trials
Clinical trials in China121
Clinical trials in USA84
Clinical trials in UK39
Clinical trials in Ireland13
Clinical trials in India9

A trial with sites in more than one country appears in each of those registers.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records โ€” it is not written from memory, and nothing here describes how Cyclophosphamide works or whether it is effective. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Cyclophosphamide (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician โ€” our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us โ€” we correct promptly and log it.